PRTKのチャート
PRTKの企業情報
| symbol | PRTK |
|---|---|
| 会社名 | Paratek Pharmaceuticals Inc （パラテック・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 パラテック・ファーマスーティカルズ（Paratek Pharmaceuticals Inc.）は臨床段階のバイオ医薬品会社である。同社はテトラサイクリン化学に基づいた治療薬の開発と商品化に従事する。同社の製品候補は抗菌剤オマダサイクリンおよびサルサイクリンである。オマダサイクリンは、地域社会が獲得した細菌感染症に罹患している患者の経験的な単独療法の選択肢として使用するために開発された抗生物質である。サリシクリンは、にきびおよび酒さの治療に使用するために設計されたテトラサイクリン由来化合物である。その他の製品候補は、テトラサイクリン由来の分子実体であり、テトラサイクリンクラスの認識された免疫調節、抗炎症および他の有益な特性を利用するように設計されている。これらの研究段階プログラムには、多発性硬化症、脊髄性筋萎縮、慢性関節リウマチおよび炎症性腸疾患などの全身性炎症性疾患のための製品候補が含まれる。 パラテック・ファ―マシュ―ティカルズは米国のバイオ医薬品会社。細菌感染症用抗生物質の開発と商業化に従事。製品候補には、急性皮膚・皮膚組織感染症や尿路感染症治療用のテトラサイクリン系抗生物質オマダサイクリン、およびにきび・ロザケア治療用のテトラサイクリン系抗生物質WC3035がある。本社はマサチュ―セッツ州。 Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use. |
| 本社所在地 | 75 Park Plaza Boston MA 02116 USA |
| 代表者氏名 | Michael F. Bigham マイケル・F・ビガム |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 617-807-6600 |
| 設立年月日 | 36923 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 83人 |
| url | www.transcept.com |
| nasdaq_url | https://www.nasdaq.com/symbol/prtk |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -94.63600 |
| 終値（lastsale） | 10.31 |
| 時価総額（marketcap） | 327132681.19 |
| 時価総額 | 時価総額（百万ドル） 296.35490 |
| 売上高 | 売上高（百万ドル） 5.13400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 250.86190 |
| 当期純利益 | 当期純利益（百万ドル） -100.70000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Paratek Pharmaceuticals Inc revenues decreased 99% to $50K. Net loss increased 25% to $57.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and administrative - Balancing increase of 51% to $18.9M (expense) Interest expense increase of 95% to $4.4M (expense). |
PRTKのテクニカル分析
PRTKのニュース
Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9 2023/05/01 12:30:00 GlobeNewswire
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m. EDT to report financial results for first quarter 2023. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company''s website at www.ParatekPharma.com . Domestic investors wishing to participate in the call will dial: 800-920-3371 and international investors will dial: +1-212-231-2909. The conference ID is 22026760. Investors can also access the call at: https://viavid.webcasts.com/starthere.jsp?ei=1611304&tp_key=5fe62a51b9 About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The company’s lead commercial product, NUZYRA ® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Paratek Pharmaceuticals (NASDAQ:PRTK) Stock Crosses Above Two Hundred Day Moving Average of $2.27 2023/04/19 07:02:46 EIN News Pharmaceuticals
… Thursday, March 16th. The specialty pharmaceutical company reported ($0.12) … investors. About Paratek Pharmaceuticals (Get Rating) Paratek Pharmaceuticals , Inc engages in … '' ratings for Paratek Pharmaceuticals and related companies with MarketBeat …
Paratek Pharmaceuticals (NASDAQ:PRTK) Share Price Crosses Above Two Hundred Day Moving Average of $2.27 2023/04/19 06:44:43 The AM Reporter
Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.27 and traded as high as $2.70. Paratek Pharmaceuticals shares last traded at $2.50, with a volume of 422,565 shares changing hands. Wall Street Analyst Weigh In […]
BTIG new coverage Paratek Pharma Buy 2023/04/17 08:04:34 Investing.com
https://www.investing.com/news/pro/transcept-pharmaceuticals-receives-investment-bank-analyst-rating-update-3056588
Paratek Pharmaceuticals Presenting New Data from NUZYRA (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023 2023/04/10 11:30:00 Wallstreet:Online
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that new data from studies with NUZYRA (omadacycline) will be
Paratek Pharmaceuticals: Patience Is Wearing Thin 2022/08/24 17:29:18 Seeking Alpha
Paratek Pharmaceuticals is advancing its flagship product nicely, but shareholders have not been rewarded yet. What lies ahead for PRTK stock? Read more to know.
Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) Fall -34.42% In Six Months, Here’s What We Should Expect Now 2022/08/06 19:00:00 Marketing Sentinel
During the last session, Paratek Pharmaceuticals Inc. (NASDAQ:PRTK)’s traded shares were 0.41 million, with the beta value of the company hitting 1.54. At the end of the trading day, the stock’s price was $2.61, reflecting an intraday gain of 1.16% or $0.03. The 52-week high for the PRTK share is $6.26, that puts it down … Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) Fall -34.42% In Six Months, Here’s What We Should Expect Now Read More »
Paratek Pharmaceuticals (PRTK) Q2 2022 Earnings Call Transcript 2022/08/04 05:30:40 The Motley Fool
PRTK earnings call for the period ending June 30, 2022.
Paratek Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation (NASDAQ:PRTK) 2022/08/04 04:36:52 Seeking Alpha
The following slide deck was published by Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q2 2022 Results - Earnings Call Transcript 2022/08/04 02:27:08 Seeking Alpha
Paratek Pharmaceuticals, Inc. (NASDAQ:NASDAQ:PRTK) Q2 2022 Earnings Conference Call August 03, 2022, 16:30 ET Company Participants Sarah Higgins - VP, Controller and Interim Principal…
Insider Selling: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Insider Sells 4,479 Shares of Stock 2021/12/18 13:02:42 Transcript Daily
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) insider Randall B. Brenner sold 4,479 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, December 13th. The stock was sold at an average price of $4.42, for a total transaction of $19,797.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which []
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel Sells $21,551.92 in Stock 2021/12/18 13:02:42 Dakota Financial News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel William M. Haskel sold 4,876 shares of the companys stock in a transaction dated Monday, December 13th. The shares were sold at an average price of $4.42, for a total transaction of $21,551.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is []
William M. Haskel Sells 17,178 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock 2021/12/17 13:42:46 Transcript Daily
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel William M. Haskel sold 17,178 shares of Paratek Pharmaceuticals stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $4.27, for a total value of $73,350.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is []
Randall B. Brenner Sells 15,780 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock 2021/12/17 13:42:45 Dakota Financial News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) insider Randall B. Brenner sold 15,780 shares of the firms stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $4.27, for a total value of $67,380.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. []
Head-To-Head Comparison: Paratek Pharmaceuticals (NASDAQ:PRTK) and Tricida (NASDAQ:TCDA) 2021/11/27 13:48:42 Dakota Financial News
Paratek Pharmaceuticals (NASDAQ:PRTK) and Tricida (NASDAQ:TCDA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Risk and Volatility Paratek Pharmaceuticals has a beta of 1.5, suggesting that its stock price is []